Evidence map›Paper›PMID 30862188›Full record

Trial reportNutrition and cancer2019

Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.

Laura S Rozek, Shama Virani, Emily L Bellile, Jeremy M G Taylor, Maureen A Sartor, Katie R Zarins, A Virani, C Cote, Francis P Worden, Mark E Prince Mark and 7 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrition and cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Laura S Rozeka University of Michigan , Ann Arbor , Michigan, USA.
Shama Virania University of Michigan , Ann Arbor , Michigan, USA.
Emily L Bellilea University of Michigan , Ann Arbor , Michigan, USA.
Jeremy M G Taylora University of Michigan , Ann Arbor , Michigan, USA.
Maureen A Sartora University of Michigan , Ann Arbor , Michigan, USA.ORCID 0000-0001-6155-5702
Katie R Zarinsa University of Michigan , Ann Arbor , Michigan, USA.
A Virania University of Michigan , Ann Arbor , Michigan, USA.
C Cotea University of Michigan , Ann Arbor , Michigan, USA.
Francis P Wordena University of Michigan , Ann Arbor , Michigan, USA.
Mark E Prince Marka University of Michigan , Ann Arbor , Michigan, USA.
Scott A McLeana University of Michigan , Ann Arbor , Michigan, USA.
Sonya A Duffyb Ohio State University , Columbus , Ohio, USA.
George H Yooc Karmanos Cancer Institute , Wayne State University , Detroit , Michigan 48201, USA.
Nabil F Sabad Winship Cancer Institute , Emory University , Atlanta , Georgia, USA.
Dong M Shind Winship Cancer Institute , Emory University , Atlanta , Georgia, USA.
Omer Kucukd Winship Cancer Institute , Emory University , Atlanta , Georgia, USA.
Gregory T Wolfa University of Michigan , Ann Arbor , Michigan, USA.
University of Michigan · USEmory University · USThe Ohio State University · USWayne State University · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Therapeutic Potential and Mechanism of Action of Potent Small Molecule InhibitorsP50CA097248 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2002 to 2013
$25.3M
Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA097248NIEHS NIH HHS P30 ES017885
6 · The paper itself

Abstract

aimSoy isoflavones have been suggested as epigenetic modulating agents with effects that could be important in carcinogenesis. Hypomethylation of LINE-1 has been associated with head and neck squamous cell carcinoma (HNSCC) development from oral premalignant lesions and with poor prognosis. To determine if neoadjuvant soy isoflavone supplementation could modulate LINE-1 methylation in HNSCC, we undertook a clinical trial.

methodsThirty-nine patients received 2-3 weeks of soy isoflavone supplements (300 mg/day) orally prior to surgery. Methylation of LINE-1, and 6 other genes was measured by pyrosequencing in biopsy, resection, and whole blood (WB) specimens. Changes in methylation were tested using paired t tests and ANOVA. Median follow up was 45 months.

resultsLINE-1 methylation increased significantly after soy isoflavone (P < 0.005). Amount of change correlated positively with days of isoflavone taken (P = 0.04). Similar changes were not seen in corresponding WB samples. No significant changes in tumor or blood methylation levels were seen in the other candidate genes.

conclusionThis is the first demonstration of in vivo increases in tissue-specific global methylation associated with soy isoflavone intake in patients with HNSCC. Prior associations of LINE-1 hypomethylation with genetic instability, carcinogenesis, and prognosis suggest that soy isoflavones maybe potential chemopreventive agents in HNSCC.

Indexed as

Dietary SupplementsDNA MethylationFemaleGlycine maxHead and Neck NeoplasmsHumansIsoflavonesLong Interspersed Nucleotide ElementsMaleMiddle AgedSquamous Cell Carcinoma of Head and NeckIsoflavones

Identifiers

PMID30862188
PMCPMC6513708
OpenAlexW2922142860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.